Absence of surface expression of CD137 (4-1BB) on Myeloid-derived suppressor cells

Inmunologia

Volumn 26, Issue 3, 2007, Pages 121-126

  Dubrot, J ^a   Azpilikueta, A ^a   Alfaro, C ^a   Murillo, O ^a   Arina, A ^a   Berraondo, P ^a   Hervas Stubbs S ^a   Melero, Ignacio ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

CD137; Immunosuppression; MDSCs

Indexed keywords

CD11B ANTIGEN; CD137 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL SURFACE; COLON CARCINOMA; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOID ORGAN; MAST CELL; MOUSE; NONHUMAN; SUPPRESSOR CELL; T LYMPHOCYTE;

EID: 38049046025     PISSN: 02139626     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0213-9626(07)70081-1     Document Type: Article

References (24)

1. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117: 1155-1166.
2. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296.
3. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67: 425; author reply 426.
4. + T cell tolerance in cancer. Nat Med 2007; 13: 828-835.
5. + T cells. J Clin Invest 2006; 116: 2777-2790.
6. Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 2005; 65: 11743-11751.
7. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515-520.
8. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13: 721s-726s.
9. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5: 641-654.
10. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007; 18: 226-232.
11. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2007; 25: 315-322.
12. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23: 23-68.
13. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 682-685.
14. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998; 28: 1116-1121.
15. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, et al. Eradication of established rumors in mice by a combination antibody-based therapy. Nat Med 2006; 12: 693-698.
16. Seo SK, Choi JH, Kim YH, cKang WJ, Park HY, Suh JH, et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004; 10: 1088-1094.
17. Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 1457-1465.
18. Wilcox RA, Chapoval AI, Gorski KS, Otsuji M, Shin T, Flies DB, et al. Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol 2002; 168: 4262-4267.
19. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539-554.
20. Nishimoto H, Lee SW, Hong H, Potter KG, Maeda-Yamamoto M, Kinoshita T, et al. Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood 2005; 106: 4241-4248.
21. Heinisch IV, Daigle I, Knopfli B, Simon HU. CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils. Eur J Immunol 2000; 30: 3441-3446.
22. Heinisch IV, Bizer C, Volgger W, Simon HU. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. J Allergy Clin Immunol 2001; 108: 21-28.
23. Simon HU. Evidence for a pro-apoptotic function of CD137 in granulocytes. Swiss Med Wkly 2001; 131: 455-458.
24. Polte T, Foell J, Werner C, Hoymann HG, Braun A, Burdach S, et al. CD137-mediated immunotherapy for allergic asthma. J Clin Invest 2007; 116: 1025-1036.